GIM
TEVA icon

Granahan Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Granahan Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,879
Closed -$213K – 226
2016
Q4 		$213K Buy
5,879
+666
+13% +$26.6K 0.01% 226
2016
Q3 		$240K Buy
+5,213
New +$272K 0.01% 224

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Granahan Investment Management's TEVA Position: Q1 2017 in Review

Granahan Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 5,879 shares — an estimated $213K sold.

Granahan Investment Management first reported a position in TEVA in Q3 2016 and held it in 2 quarters. The position peaked at $240K in Q3 2016. 687 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Granahan Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Granahan Investment Management sold 5,879 Teva Pharmaceuticals shares in Q1 2017, an estimated $213K.
  • Granahan Investment Management first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Granahan Investment Management's Teva Pharmaceuticals position peaked at $240K in Q3 2016.
  • 687 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Granahan Investment Management's 13F filing for Q1 2017, filed 15 May 2017.